---
title: "UroGen Pharma Ltd. (URGN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/URGN.US.md"
symbol: "URGN.US"
name: "UroGen Pharma Ltd."
industry: "Biotechnology"
datetime: "2026-03-13T19:37:22.753Z"
locales:
  - [en](https://longbridge.com/en/quote/URGN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/URGN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/URGN.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/URGN.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/URGN.US.md)


# UroGen Pharma Ltd. (URGN.US)

## Company Overview

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.urogen.com](https://www.urogen.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-13T04:30:16.000Z

**Overall: C (0.51)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 109 / 404 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 21.45% |  |
| Net Profit YoY | -20.98% |  |
| P/B Ratio | -8.67 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 914740041.20 |  |
| Revenue | 109788000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 268.63% | A |
| Profit Margin | -139.81% | E |
| Gross Margin | 88.66% | A |
| Revenue YoY | 21.45% | A |
| Net Profit YoY | -20.98% | D |
| Total Assets YoY | -29.84% | E |
| Net Assets YoY | -1098.16% | E |
| Cash Flow Margin | -71.53% | D |
| OCF YoY | 21.45% | A |
| Turnover | 0.45 | C |
| Gearing Ratio | 152.62% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - UroGen Pharma Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "21.45%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-20.98%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-8.67",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "914740041.20",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "109788000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "268.63%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-139.81%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "88.66%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "21.45%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-20.98%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-29.84%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-1098.16%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-71.53%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "21.45%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.45",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "152.62%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.96 | 397/404 | - | - | - |
| PB | -8.67 | 524/404 | - | - | - |
| PS (TTM) | 8.33 | 150/404 | 10.51 | 9.05 | 5.71 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (STOK.US) | A | A | B | A | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-09T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 75% |
| Overweight | 1 | 13% |
| Hold | 1 | 13% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 18.45 |
| Highest Target | 55.00 |
| Lowest Target | 16.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/URGN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/URGN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/URGN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/URGN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**